Melinta Therapeutics, Inc. (NASDAQ:MLNT) reached a new 52-week high and low during mid-day trading on Friday . The stock traded as low as $6.65 and last traded at $6.90, with a volume of 272549 shares traded. The stock had previously closed at $7.10.
Several brokerages have recently weighed in on MLNT. Zacks Investment Research downgraded shares of Melinta Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, February 8th. BidaskClub downgraded shares of Melinta Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $3.56.
The company has a market cap of $241.20, a price-to-earnings ratio of -0.32 and a beta of 1.37. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.38 and a current ratio of 4.72.
Several hedge funds have recently made changes to their positions in MLNT. Vatera Holdings LLC purchased a new position in shares of Melinta Therapeutics in the fourth quarter valued at $106,325,000. BlackRock Inc. bought a new position in Melinta Therapeutics during the 4th quarter valued at $9,550,000. Millennium Management LLC bought a new position in Melinta Therapeutics during the 4th quarter valued at $4,407,000. Sphera Funds Management LTD. bought a new position in Melinta Therapeutics during the 4th quarter valued at $3,160,000. Finally, Deutsche Bank AG bought a new position in Melinta Therapeutics during the 4th quarter valued at $1,464,000. Institutional investors and hedge funds own 36.99% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3336173/melinta-therapeutics-mlnt-sets-new-12-month-high-and-low-at-6-65.html.
About Melinta Therapeutics
Melinta Therapeutics, Inc develops and commercializes novel antibiotics designed to provide therapeutic solutions. The Company’s lead product is Baxdela, an antibiotic approved by the United States food and drug administration (FDA) for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Receive News & Ratings for Melinta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Melinta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.